Stock Events

Stock Events

Kezar Life Sciences 

$7.69
0
+$0+0% Tuesday 03:22

Statistics

Day High
7.71
Day Low
7.69
52W High
-
52W Low
-
Volume
372
Avg. Volume
-
Mkt Cap
56.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Next
-2.06
-1.83
-1.6
-1.37
Expected EPS
-1.3725
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-167.47MNet Income

Analyst Ratings

$6.00Average Price Target
The highest estimate is 7.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KZR.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, directly competing in the rare disease space similar to Kezar's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals targets cystic fibrosis and other rare diseases, overlapping with Kezar's therapeutic areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for rare genetic diseases, competing in the same niche as Kezar.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing for rare diseases, representing direct competition in innovative treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis AG has a broad portfolio including treatments for autoimmune diseases and rare conditions, competing across several of Kezar's interest areas.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology and rare diseases, areas where Kezar Life Sciences is also aiming to develop treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a diverse portfolio including oncology and inflammatory diseases, directly competing with Kezar's research focus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a broad focus including treatments for cancer and autoimmune diseases, overlapping with Kezar's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovative treatments in areas like oncology and rare diseases, competing with Kezar's development pipeline.

About

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Show more...
CEO
ISIN
US49372L2097

Listings

F
DE
2KZ0.F
XNAS
US
KZR
BOATS
BOATS
KZR.BOATS

0 Comments

Share your thoughts

FAQ

What is Kezar Life Sciences stock price today?▼
The current price of KZR.BOATS is $7.69 USD — it has increased by +0% in the past 24 hours. Watch Kezar Life Sciences stock price performance more closely on the chart.
What is Kezar Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kezar Life Sciences stocks are traded under the ticker KZR.BOATS.
What is Kezar Life Sciences market cap?▼
Today Kezar Life Sciences has the market capitalization of 56.31M
When is the next Kezar Life Sciences earnings date?▼
Kezar Life Sciences is going to release the next earnings report on May 07, 2026.
What were Kezar Life Sciences earnings last quarter?▼
KZR.BOATS earnings for the last quarter are -1.53 USD per share, whereas the estimation was -2.06 USD resulting in a +25.64% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kezar Life Sciences revenue for the last year?▼
Kezar Life Sciences revenue for the last year amounts to 0 USD.
What is Kezar Life Sciences net income for the last year?▼
KZR.BOATS net income for the last year is -167.47M USD.
When did Kezar Life Sciences complete a stock split?▼
Kezar Life Sciences has not had any recent stock splits.